GLOBAL DEAL SYNDICATION

HBS Alumni Angels syndicates selected deals across the full global membership of its 14 chapters. This enables selected deals from one chapter to reach a global network of accredited investor alumni. This is a unique benefit of being a member in a local HBS Alumni Angel chapter. Investment decisions are made and executed individually following a global webinar. Once investments are made, investors often assist companies in other areas as formal or informal advisers. For details on how the process works, please scroll down.

UPCOMING SYNDICATION CALL

20210819 Landsdowne Labs.jpg

GLOBAL SYNDICATED INVESTMENT PRESENTATION: LANDSDOWNE LABS

August 19, 2021 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter: Melissa Fensterstock, MBA'12, CEO & Co-Founder of Landsdowne Labs
Complimentary for HBS Angels Members

 

About this event:
On behalf of the Boston chapter, we would like to share the following investment opportunity:

Summary

Landsdowne Labs is a battery technology company on a mission to set a new, safer standard for the button battery market. The company’s proprietary ChildLok™ technology is designed to deactivate coin cell batteries upon ingestion, made possible by advanced material science. Spun out of the world-renowned Langer Labs at MIT and Karp Labs at Harvard, Landsdowne Labs is commercializing this groundbreaking battery design for global companies seeking a turnkey, low cost solution to the growing button battery health crisis.  The company is exploring a near term M&A opportunity and is finalizing a high priority JDA with a strategic partner. 

 

The Problem: A growing health epidemic

  • Every year in the United States, more than 35,000 people of all ages swallow button batteries of which only 10% are reported per year (Jatana et al). These are used to power hearing aids, watches, toys, games, flashing jewelry, singing greeting cards, remote control devices, and many other items (National Poison Control Center).

  • According to a new study in the journal Pediatrics, the rate of foreign-body ingestions among children under age 6 nearly doubled in the two decades after 1995.

  • During the pandemic, battery ingestions increase 93% (CPSC)

  • As a whole, battery ingestions increased 150-fold during the study period, the researchers reported. Button batteries, which can be fatal if ingested, were found to be the most common type of battery that young children swallowed.

  • When a battery is swallowed, it can trigger a series of chemical reactions that could result in burns, causing “significant tissue injury even within two hours,” according to the American Academy of Pediatrics, and potentially lead to perforation or hemorrhage.

  • See an emotional mom's video here on the problem at hand.

 

The Solution: A new, safer standard for button batteries

  • With coin cell sales on the rise, battery companies are under mounting pressure to seek out a solution that goes beyond the traditional methods of child-resistant packaging and marketing to eliminate the health hazards of battery ingestion 

  • ChildLok™ is a first-of-its-kind, preventative technology designed to solve the problem at the root cause 

  • Proprietary, sophisticated and battery manufacturer-agnostic coating technology is designed to deactivate the battery’s power upon ingestion, made possible by advanced material science

  • Through deactivation, some of the risks associated with accidental button battery ingestion – such as chemical burns, permanent tissue damage to the esophagus, and even death may be reduced.   

  • A low-cost, turnkey solution that seamlessly integrates into existing manufacturing supply chain without sacrificing battery performance  

  •  The answer to a growing public health issue widely recognized and prioritized by regulatory bodies, clinicians, retailers and the public at large

 

Markets, Commercialization, & IP

With roughly 10B button batteries sold each year and with the market growing at nearly 20% per year, the segment is an attractive category within the battery industry. Landsdowne Labs has a number of filed and issued patents. The company is rooted in over a decade of research, testing, and validation. Landsdowne Labs is in the process of executing a JDA with one of the largest metal and mining companies in the world (pending legal signatures).  We are running an M&A process that will kick off this fall, led by a top tier investment bank.  We consider an investment in Landsdowne to be a unique opportunity to see a potential near-term liquidity event.

 

Raise

Landsdowne Labs has previously raised $2.8M in a priced equity round in 2018. The company is finishing up a convertible note ( up to $2M) with 1.5M closed or committed and a handful of groups in process. The terms of the note are cap of $15M, 20% discount, 6% interest or 1.75x liquidation preference. The note is securitized.

LUPII

LANDSDOWNE LABS

20210819 Fensterstock.jpg

CEO, LANDSDOWNE LABS

Melissa Fensterstock
Melissa Fensterstock is a serial entrepreneur and CEO of Landsdowne Labs. She has extensive experience in biotech, medtech, and consumer products.  Melissa holds an MBA from Harvard Business School where she was a Robert S. Kaplan Life Science Scholar, an MPhil in Bioscience Enterprise from the University of Cambridge where she was an Overseas Trust Scholar, and a BA in Neuroscience from Johns Hopkins University. 

SAVE THE DATE

20210906 Moxie_Scrubs_Logo 500X135.jpg

GLOBAL SYNDICATED INVESTMENT PRESENTATION:
LANDSDOWNE LABS

September 6, 2021 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter: Alicia Tulsee, Founder of Moxie Scrubbs
Complimentary for HBS Angels Members
CHECK BACK SOON FOR INFORMATION & REGISTRATION!

 

RECENT SYNDICATION CALL

20210722 RocketStar.png

GLOBAL SYNDICATED INVESTMENT PRESENTATION:
ROCKETSTAR

July 22, 2021 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter: Founder & CEO Christopher Craddock of ROCKETSTAR
Complimentary for HBS Angels Members

 

About this event:
On behalf of the NY chapter, we would like to share the following investment opportunity:

Summary

RocketStar is developing a new type of Aerospike Rocket Engine that will give the market a true Single Stage to Orbit Reusable Launch Vehicle. We have completed our prototype and have built a rocket scheduled for a small satellite launch in September 2021. We have early traction with several satellite companies to lift them to Low Earth Orbit a partnership agreement with NASA.

 

Problem

Current satellite launch providers have to spend 50 to 100 million dollars on a multi-stage rocket, much if not all of which gets thrown away. This leads to high launch cost and lengthy lead times as a new rocket must be built every single time.

 

Solution

Our product will reduce overall weight, drive down cost by a factor of ten, and allow us to fly true Single Stage to Orbit Reusable Launch Vehicles. The Aerospike engine is up to 20% more efficient than current competitive rocket engines, thus it is not evolutionary improvement, but a revolutionary one. It will make low earth orbit (LEO) transport and beyond inexpensive compared to existing solutions and drastically shorten lead times given its reusability.

 

Markets, Commercialization, & IP

We are targeting the $5 Billion a year launch services market. We plan to start lifting small satellites, of which we have several Letters of Intent with, and move into different launch services categories as we grow. We plan to leverage our network and our board's network to penetrate the space industry. Our technology and our customer service will retain clients for the long term. Our customers are small satellite companies. Currently, the wait time for launching is at least 2 years, and small satellites are secondary payload compared to traditional large satellites. There are currently limited dedicated small satellite launchers that are flying today. We will have both a technological and early mover advantage, and due to our rockets being reusable, we will be able to charge much less than anyone. Proprietary aerospike technology with patent pending gives us an advantage as an early entrant, and also our rapid prototyping and execution are distinctive. We went from concept to launch in 6 months, which is unheard of in the industry. Separately, we have filed a provisional patent on a new type of plasma thruster that has at least 4 times more thrust than the competition

 

Raise

RocketStar has closed over $900k of a convertible note Seed round not to exceed $2M.  The convertible notes have a $5M conversion cap and 20% conversion discount bearing 7% interest.  Capital from this raise will support upcoming prototype launch and initial funding of the next orbital vehicle. HBSAANY members have invested $125k in this round.  The firm has retained investment bankers Oberon Securities to raise the Series A equity round to be kicked off following the launch in September. 

LUPII

ROCKETSTAR

20210722 Craddock.jpg

Founder & CEO, ROCKETSTAR

Christopher Craddock
B.S. in Physics and over 15 years of entrepreneurial and financial experience including founding and running a commodities trading company on Wall Street. With a decade of running his own company, he knows firsthand the pain of creating, running and living a startup –his experience is not just paper, but his experience is real world.

PAST SYNDICATED COMPANIES

20210722 RocketStar
20210614 MomiBaby logo cropped
20210527 Cognoptix logo 200X36
20210427 Synd Call LUPII_LOGO 200X
20210121 TANG app 2 150X
20201209 Wave logo 200X
20201203 Beckon logo
20201119%20Syndication%20Dover%20Microsy
20200826 New View logo
20200813%2520COLORONLY%2520logo_edited_e
20200811 BrightSpec Logo
unnamed
Wheeli
Vaporox
Cargo Chief
MyndBlue
Health Hero
agencyQ
HIPAAtrek
IrriGreen
SIA
Tire Agent
Wibmo

HOW IT WORKS

Use arrows on the side to navigate

1. HOST CHAPTER

A company must meet a threshold of member investment in one of our HBS Alumni Angel Chapters listed here. The leadership of the host chapter nominates the company for global syndication and provides a local member contact to act as syndication lead and a company contact.

CRITERIA

Ideally, for global syndication a company should meet the following requirements:

  • Local host chapter members committed to invest at least $50,000* and local chapter forwards deal to global for syndication; 

  • Company assures at least $50,000-100,000 investible capacity;

  • Company provides at least 2 weeks for due diligence following the webinar, prior to requiring an investment decision;

  • Minimum individual investment amount is set at $25,000 or less;

  • Company agrees to a one-time admin fee of $1500.

The Global Syndication Committee selects the most suitable company candidates from the 15 participating HBSAA chapters and is aiming to host monthly webinars. 

*NY and other larger chapters may have a $100,000 min.